Literature DB >> 19901853

Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure.

Jessamy A Boyd1, Jessica L Hubbs, Dong W Kim, Donna Hollis, Lawrence B Marks, Chris R Kelsey.   

Abstract

INTRODUCTION: Most adjuvant lung cancer trials only report first sites of failure. The relative timing of local (i.e., local/regional) versus distant recurrence after surgery could potentially affect reported rates of local failure. We assessed this phenomenon in a large group of patients undergoing surgery for early-stage lung cancer.
METHODS: This institutional review board-approved retrospective study identified all patients who underwent surgery at Duke University Medical Center for pathologic stages I to II non-small cell lung cancer between 1995 and 2005. Medical records and pertinent radiographs were reviewed to assess for local and distant sites of recurrence. Both first and subsequent failures were examined. The time interval between surgery and date of local and/or distant failure was compared using the Mann-Whitney U test.
RESULTS: Of 975 patients undergoing surgery, 250 patients developed recurrent disease (43 local only, 110 distant only, and 97 both). The median time from surgery to local failure was 13.9 months (range, 1-79). The median time to distant failure was 12.5 months (range, 1-79 months). These were not significantly different (p = 0.34). Among 97 patients who experienced both local and distant failure, 72 (74%) failed at both sites simultaneously, 19 (20%) failed at local sites first, and 6 (6%) failed at distant sites first.
CONCLUSIONS: The time interval from surgery to either local or distant failure is not significantly different. Patterns of failure analyses in which only first sites of failure are scored will underestimate the frequency of local recurrence. Nevertheless, the magnitude of this error is expected to be small.

Entities:  

Mesh:

Year:  2010        PMID: 19901853     DOI: 10.1097/JTO.0b013e3181c20080

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  23 in total

Review 1.  Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer.

Authors:  Fabrizio Tabbò; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2019-11

2.  Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer.

Authors:  Xuebin Yang; Yongjun Liu; Haresh Mani; Jeffrey Olson; Gary Clawson; Carla Caruso; Richard Bruggeman; John M Varlotto; Dani S Zander; Negar Rassaei
Journal:  Pathol Oncol Res       Date:  2016-07-13       Impact factor: 3.201

3.  Editorial on "Long-term survival outcome after postoperative recurrence of non-small cell lung cancer: who is 'cured' from postoperative recurrence?"

Authors:  Joachim Pfannschmidt
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 4.  Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.

Authors:  Justin Yeh; Kristen A Marrone; Patrick M Forde
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 5.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 6.  Recurrence after surgery in patients with NSCLC.

Authors:  Hidetaka Uramoto; Fumihiro Tanaka
Journal:  Transl Lung Cancer Res       Date:  2014-08

Review 7.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 8.  Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Sonam Puri; Michael Shafique; Jhanelle E Gray
Journal:  Curr Treat Options Oncol       Date:  2018-06-21

Review 9.  Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.

Authors:  Laura Gutierrez-Sainz; Patricia Cruz-Castellanos; Oliver Higuera; Javier de Castro-Carpeño
Journal:  Curr Treat Options Oncol       Date:  2021-08-23

10.  The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms.

Authors:  Max Dahele; Suresh Senan
Journal:  Cancer Res Treat       Date:  2011-06-30       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.